Rights and permissions
About this article
Cite this article
Selecting NSCLC patients for erlotinib pays off in France. Pharmacoecon. Outcomes News 632, 1 (2011). https://doi.org/10.2165/00151234-201106320-00001
Published:
Issue Date:
DOI: https://doi.org/10.2165/00151234-201106320-00001